Page 16 - Coronavirus Vaccine

Data story: India logs 5,221 new Covid cases; death toll at 528,165

India has added 38,135 cases in the past 7 days

DCGI nod sought for phase-3 study of intranasal Covid vax in 5-18 age group

Hyderabad-based firm Bharat Biotech has sought permission from the drug regulator to conduct phase-3 study of its intranasal COVID-19 vaccine in the 5 to 18 age group. On September 6, the Drugs Controller General of India (DCGI) had approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those aged above 18 years. "Now the Hyderabad based firm has submitted an application seeking permission to conduct phase-3, multicenter study to evaluate the safety, reactogenicity and immunogenicity of iNCOVACC (BBV154) in those aged 18 to 5 years," an official source told PTI. iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said. BBV154 has been specifically formulated to allow intranasal delivery. "Being an intranasal vaccine, BBV154 may produce local antibodies in the up

Data story: India logs 5,076 new Covid cases; death toll at 528,150

India has added 38,824 cases in the past 7 days.

Canada approves Pfizer Covid-19 vaccine for kids under five years

Health Canada has approved Pfizer's Covid-19 vaccine to immunise children under the age of five

Delhi logs 123 fresh Covid cases, 4 deaths in a day; active tally at 788

Delhi on Friday recorded 123 fresh COVID-19 cases with a positivity rate of 1.06 per cent while four more people succumbed to the disease, according to data shared by the health department here. The new cases were detected from 11,567 tests conducted the previous day, the department said in its latest bulletin. With the fresh cases and fatalities, Delhi's infection tally increased to 20,01,432 and the death toll reached 26,491, it said. On Thursday, the city logged 182 COVID-19 cases with a positivity rate of 1.37 per cent and three fatalities. The day before, it recorded 177 COVID-19 cases with a positivity rate of 1.36 per cent, and two deaths. The government did not issue a bulletin on Monday and Tuesday. On Sunday, the national capital recorded 218 cases with a positivity rate of 1.93 per cent. A day before, the city had logged 236 cases with a positivity rate of 1.68 per cent and three deaths. The number of active Covid cases in Delhi stands at 788. As many as 585 patients a

What are nasal vaccines and how do they work?

The Drugs Controller General of India has approved the first intra-nasal Covid-19 vaccine for restricted use. A few drops in both the nostril will keep the virus at bay. Let us find out more

Two Israel-based antibodies may fight all known Covid-19 strains: Study

Scientists in Israel have isolated two antibodies from the immune system of recovered COVID-19 patients that may neutralise all known strains of SARS-CoV-2, including Omicron, with up to 95 per cent efficiency. The team at Tel Aviv University noted that targeted treatment with antibodies and their delivery to the body in high concentrations may serve as an effective substitute for vaccines, especially for at-risk populations and those with weakened immune systems. By using antibody treatment, there is a possibility that the need to provide repeated booster shots to the entire population every time a new variant emerges will be eliminated, the researchers said. The study, recently published in the journal Communications Biology, is a continuation of a preliminary research conducted in October 2020, at the height of the COVID-19 crisis. At that time, the team sequenced all the B immune system cells from the blood of people who had recovered from the original COVID-19 strain in Israel

LIVE: Union Cabinet approves policy on long-term leasing of Railways' land

300 cargo terminals will be developed in 5 years, says Union Minister Anurag Thakur on Union Cabinet decisions

High-risk groups priority for latest adapted Covid-19 vaccines: ECDC

The European Centre for Disease Prevention and Control said that individuals in high-risk groups and healthcare workers should be prioritised when the latest adapted Covid-19 vaccines are rolled out.

Data story: India logs 5,379 new Covid cases; death toll at 528,057

India has so far administered 2,139,149,934 vaccine doses

Top headlines: India's first nasal vaccine for Covid-19; new seat belt rule

Business Standard brings you the top headlines at this hour

India's first nasal vaccine for Covid-19 gets DCGI nod for emergency use

Bharat Biotech's iNCOVACC cleared for 2-dose regimen

Updated Covid boosters ready in US this week, says White House

US health officials said on Tuesday that the vaccine is moving closer to an annual jab, as with flu shots

Intranasal Covid vaccine will be global game changer: Bharat Biotech MD

Phase III trials were conducted for safety, and immunogenicity in about 3,100 subjects, in 14 trial sites across India

Bharat Biotech's intranasal Covid vaccine gets DCGI's nod for emergency use

The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Union Health Minister Mansukh Mandaviya tweeted. He said this step will further strengthen "our collective fight" against the pandemic. India has harnessed its science, research and development (R&D), and human resources in the fight against COVID-19 under Prime Minister Narendra Modi's leadership, he said. "With the science-driven approach & Sabka Prayas, we will defeat COVID-19," Mandaviya also said. The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Top headlines:India gets intranasal Covid vax; Moody's retains India rating

The global ratings agency said it will maintain its long-term sovereign debt credit rating and outlook on Asia's third largest economy

Heart inflammation risk after Covid-19 booster rare in young men: Study

The risk of developing myocarditis among males ages 16 to 19 years are about one in 15,000 after the third dose of the Pfizer-BioNTech Covid-19 vaccine, however the cases are rare and mild.

Data story: India logs 4,417 new Covid cases; active tally at 52,336

India has added 48,277 cases in the past 7 days

World's first coronavirus vaccine you can inhale approved in China

China's National Medical Products Administration approved CanSino's Ad5-nCoV for emergency use as a booster vaccine